Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia
Publication date
2024-11
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
Marginal Zone Lymphoma (MZL) and Waldenström's Macroglobulinemia (WM) are indolent lymphomas that both arise from post germinal center lymphocytes. Both can secrete a monoclonal protein but high levels are mostly only seen in WM. The MYD88 L256P somatic mutation that is present in an estimated 95% of patients with WM has helped greatly in differentiating the two lymphomas. Several large clinical studies with new drugs have been performed that have provided new treatment options for both MZL and WM patients. In this short review we will discuss the recent literature published and provide some recommendations.
Keywords
marginal zone lymphoma, treatment, Waldenstrom macroglobulinemia, Hematology, Oncology, Cancer Research, Review, Journal Article
Citation
Amaador, K, Thieblemont, C, Trotman, J & Minnema, M C 2024, 'Recent updates in the indolent lymphomas : Update on marginal zone lymphoma and Waldenström's macroglobulinemia', Hematological Oncology, vol. 42, no. 6, e3210. https://doi.org/10.1002/hon.3210